Biological effects induced by variable levels of BCR-ABL protein in the pluripotent hematopoietic cell line UT-7

Leukemia

Volumn 14, Issue 4, 2000, Pages 662-670

  Issaad, C ^a   Ahmed, M ^a   Novault, S ^a   Bonnet, M L ^a   Bennardo, T ^b   Varet, B ^b   Vainchenker, W ^a   Turhan, A G ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Apoptosis; BCR ABL; CML; Differentiation; UT 7

Indexed keywords

BCR ABL PROTEIN;

APOPTOSIS; ARTICLE; CELL CLONE; CELL LINE; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; WESTERN BLOTTING;

EID: 0034039177     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401730     Document Type: Article

References (37)

1. Daley GQ, Baltimore D. Transformation of an interleukin-3 dependent hematopoietic cell line by the chronic myelogenous specific P210 bcr/abl protein. Proc Natl Acad Sci USA 1988; 85: 9312-9316.
2. Kabarowski JH, Allen PB, Wiedemann LM. A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells. EMBO J 1994; 13: 5887-5895.
3. Sirard C, Laneuville P, Dick JE. Expression of bcr-abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism. Blood 1994; 83: 1575-1585.
4. Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG, Arlinghaus R, Pawson T. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 1994; 13: 764-773.
5. Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G, Gewirtz AM, Perussia B, Calabretta B. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 1995; 86: 726-736.
6. Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 1994; 269: 22925-22928.
7. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 1994; 83: 1179-1187.
8. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 1994; 83: 2038-2044.
9. Albrecht T, Schwab R, Henkes M, Peschel C, Huber C, Aulitzky WE. Primary proliferating immature myeloid cells from CML patients are not resistant to induction of apoptosis by DNA damage and growth factor withdrawal. Br J Haematol 1996; 95: 501-507.
10. Amos TA, Lewis JL, Grand FH, Gooding RP, Goldman JM, Gordon MY. Apoptosis in chronic myeloid leukaemia: normal responses by progenitor cells to growth factor deprivation, X-irradiation and glucocorticoids. Br J Haematol 1995; 91: 387-393.
11. Eaves AC, Eaves CJ. Abnormalities in the erythroid progenitor compartments in patients with chronic myelogenous leukemia (CML). Exp Hematol 1979; 7 (Suppl. 5): 65-75.
12. Issaad C, Vainchenker W. Growth of erythroid colonies in chronic myelogenous leukemia is independent of erythropoietin only in the presence of steel factor. Blood 1994; 84: 3447-3456.
13. Druker BJ, Tamura S, Buchdunger E, Ohno S, Bagby GC, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the abl tyrosine kinase on the growth of BCR-ABL positive cells. Nature Med 1996; 2: 561-566.
14. Cambier N, Chopra K, Strasser A, Metcalf D, Elefanty AG. BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a close-dependent manner. Oncogene 1998; 16: 335-348.
15. Komatsu N, Nakauchi H, Miwa A, Ishihara T, Eguchi M, Moroi M, Okada M, Sato Y, Wada H, Yawata Y, Suda T, Miura Y. Establishment and characterization of a human leukemic cell line with megakaryocytic features: dependency on granulocyte-macrophage colony-stimulating factor, interleukin 3, or erythropoietin for growth and survival. Cancer Res 1991; 51: 341-348.
16. Turhan AG, Eaves CJ, Sutherland HJ, Humphries RK. Retrovirus-mediated transfer of the BCR-ABL (p210) gene to highly purified primitive human hemopoietic cells and the generation of Epo-independent progeny. Blood 1991; 78 (Suppl. 1): 1341.
17. Hariharan IK, Adams JM, Cory S. bcr-abl oncogene renders myeloid cell line factor independent: potential autocrine mechanism in chronic myeloid leukemia. Oncogene Res 1988; 3: 387-399.
18. Hawley RG, Lieu FH, Fong AZ, Hawley TS. Versatile retroviral vectors for potential use in gene therapy. Gene Therapy 1994; 1: 136-138.
19. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Meth 1991; 139: 271-279.
20. Bowtell DD, Cory S, Johnson GR, Gonda TJ. Comparison of expression in hemopoietic cells by retroviral vectors carrying two genes. J Virol 1988; 62: 2464-2473.
21. Artelt P, Grannemann R, Stocking C, Friel J, Bartsch J, Hauser H. The prokaryotic neomycin-resistance-encoding gene acts as a transcriptional silencer in eukaryotic cells. Gene 1991; 99: 249-254.
22. Clarkson BD, Strife A, Wisniewski D, Lambek C, Carpino N. New understanding of the pathogenesis of CML: a prototype of early neoplasia. Leukemia 1997; 11: 1404-1428.
23. Matsuguchi T, Salgia R, Hallek M, Eder M, Druker B, Ernst TJ, Griffin JD. Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL. J Biol Chem 1994; 269: 5016-5021.
24. Okuda K, Matulonis U, Salgia R, Kanakura Y, Druker B, Griffin JD. Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1. Exp Hematol 1994; 22: 1111-1117.
25. Carlesso N, Frank DA, Griffin JD. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 1996; 183: 811-820.
26. Carpino N, Wisniewski D, Strife A, Marshak D, Kobayashi R, Stillman B, Clarkson B. p62(dok): a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells. Cell 1997; 88: 197-204.
27. Dai Z, Quackenbush RC, Courtney KD, Grove M, Cortez D, Reuther GW, Pendergast AM. Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway. Genes Dev 1998; 12: 1415-1424.
28. Eaves AC, Cashman JD, Gaboury LA, Kalousek DK, Eaves CJ. Unregulated proliferation of primitive chronic myeloid leukemia progenitors in the presence of normal marrow adherent cells. Proc Natl Acad Sci USA 1986; 83: 5306-5310.
29. Laneuville P, Sun G, Timm M, Vekemans M. Clonal evolution in a myeloid cell line transformed to interleukin-3 independent growth by retroviral transduction and expression of p210bcr/abl. Blood 1992; 80: 1788-1797.
30. Guo JQ, Lian J, Glassman A, Talpaz M, Kantarjian H, Deisseroth AB, Arlinghaus RB. Comparison of bcr-abl protein expression and Philadelphia chromosome analyses in chronic myelogenous leukemia patients. Am J Clin Pathol 1996; 106: 442-448.
31. Guo JQ, Lian JY, Xian YM, Lee MS, Deisseroth AB, Stass SA, Champlin RE, Talpaz M, Wang JY, Arlinghaus RB. BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy. Blood 1994; 83: 3629-3637.
32. Gisslinger H, Kurzrock R, Wetzler M, Tucker S, Kantarjian H, Robertson B, Talpaz M. Apoptosis in chronic myelogenous leukemia: studies of stage-specific differences. Leuk Lymphoma 1997; 25: 121-133.
33. Gaiger A, Henn T, Horth E, Geissler K, Mitterbauer G, Maier-Dobersberger T, Greinix H, Mannhalter C, Haas OA, Lechner K, Lion T. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood 1995; 86: 2371-2378.
34. Pierce A, Owen-Lynch PJ, Spooncer E, Dexter TM, Whetton AD. p210 Bcr-Abl expression in a primitive multipotent haematopoietic cell line models the development of chronic myeloid leukaemia. Oncogene 1998; 17: 667-672.
35. Ahmed M, Dusanter-Fourt I, Bernard M, Mayeux P, Hawley RG, Bennardo T, Novault S, Bonnet ML, Gisselbrecht S, Varet B, Turhan AG. BCR-ABL and constitutively active erythropoietin receptor (cEpoR) activate distinct mechanisms for growth factor-independence and inhibition of apoptosis in Ba/F3 cell line. Oncogene 1998; 16: 489-496.
36. Kabarowski JH, Allen PB, Wiedemann LM. A temperature sensitive p210 BCR-ABL mutant defines the primary consequences of BCR-ABL tyrosine kinase expression in growth factor dependent cells. EMBO J 1994; 13: 5887-5895.
37. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995; 86: 3118-3122.